IsoTis and Modex' biosurgery merger to capitalise on consolidation
This article was originally published in Clinica
Executive Summary
Dutch tissue engineering company IsoTis and Modex Therapeutics, the Swiss manufacturer of human skin equivalent products are to merge to form one of Europe's leading tissue repair companies using cultured cells and biomaterials. The new company, to be called IsoTis, will initially focus on orthopaedics and skin management and will operate in a market valued worldwide at some $16bn, said an IsoTis spokesperson.